Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AEF 0117

Drug Profile

AEF 0117

Alternative Names: AEF0117

Latest Information Update: 22 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aelis Farma
  • Developer Aelis Farma; Columbia University; National Institute on Drug Abuse; New York State Psychiatric Institute
  • Class Drug withdrawal therapies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Substance-related disorders

Most Recent Events

  • 15 Feb 2019 Aelis Farma suspends phase II trial in Substance-related disorders in USA (NCT03717272)
  • 24 Oct 2018 Aelis Farma plans a phase II trial for Substance-related disorders in USA (NCT03717272)
  • 13 May 2018 Phase-II clinical trials in Substance-related disorders in USA (PO) (NCT03717272)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top